Detalhe da pesquisa
1.
CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
J Immunol
; 190(9): 4868-76, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23530148
2.
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.
Int J Cancer
; 131(4): E449-62, 2012 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22095289
3.
DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Eur J Immunol
; 39(5): 1361-8, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19404979
4.
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cancer Immunol Immunother
; 59(11): 1611-9, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20582413
5.
In vitro antitumor lymphocyte generation using dendritic cells and innate immunity mechanisms as tumor cell treatments.
Anticancer Res
; 27(4B): 2385-92, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17695529
6.
Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
Anticancer Res
; 25(3B): 2177-85, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16158961
7.
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
J Immunother
; 33(4): 402-13, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20386466
8.
Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
Cancer Immunol Immunother
; 52(11): 699-707, 2003 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12879292